Silver Point Finance, LLC v. Deutsche Bank Trust CompanyAmericas (In re K-V Discovery Solutions, Inc.)

496 B.R. 330, 2013 Bankr. LEXIS 3501, 58 Bankr. Ct. Dec. (CRR) 128
CourtUnited States Bankruptcy Court, S.D. New York
DecidedAugust 27, 2013
DocketCase No. 12-13346 (ALG) (Jointly Administered); Adv. Pro. No. 13-1381 (ALG)
StatusPublished
Cited by2 cases

This text of 496 B.R. 330 (Silver Point Finance, LLC v. Deutsche Bank Trust CompanyAmericas (In re K-V Discovery Solutions, Inc.)) is published on Counsel Stack Legal Research, covering United States Bankruptcy Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Silver Point Finance, LLC v. Deutsche Bank Trust CompanyAmericas (In re K-V Discovery Solutions, Inc.), 496 B.R. 330, 2013 Bankr. LEXIS 3501, 58 Bankr. Ct. Dec. (CRR) 128 (N.Y. 2013).

Opinion

Chapter 11

CORRECTED MEMORANDUM DECISION AND ORDER

Allan L. Gropper, UNITED STATES BANKRUPTCY JUDGE

FACTS

The Principal Indenture Provisions at Issue

On May 16, 2003, K-V Pharmaceutical Company (“KV”) issued $200 million of [332]*3322.5% Contingent Convertible Subordinated Notes due 2033 (the “Convertible Notes”) pursuant to an indenture, dated as of May 16, 2003 (the “Convertible Notes Indenture”) with Deutsche Bank Trust Company Americas, as trustee. (Def. Ex. 1, Convert. Indent.) The Convertible Notes Indenture is governed by New York law. (Convert. Indent., § 12.09).

Section 11.01 of the Convertible Notes Indenture provides that payment of any amounts due on the Convertible Notes are “subordinated in right of payment, in cash or cash equivalent, to the extent and in the manner stated in this Article XI to the prior payment in full when due of all existing and future Senior Indebtedness of [KV].” (Def. Ex. 1, Convert. Indent. § 11.01.) With respect to a distribution of KV’s assets in a bankruptcy reorganization, § 11.02 provides that “the holders of all Senior Indebtedness shall first be entitled to receive payment in full, in cash or cash equivalent, of the principal thereof, the interest thereon and any other amounts then due thereon before the [holders of the Convertible Notes] are entitled to receive payment on account of the principal of or interest on or any other amounts due on the [Convertible Notes].” (Def. Ex. 1, Convert. Indent. § 11.02.) Senior Indebtedness is defined in § 1.01 of the Convertible Notes Indenture as

the principal of, premium, if any, interest, including, with respect to the Credit Facility, all interest accrued subsequent to the commencement of any bankruptcy or similar proceeding, whether or not a claim for post-petition interest is allowable as a claim in any such proceeding, and rent payable on or in connection with, and all fees, costs, expenses and other amounts accrued or due on or in connection with, [KV’s] Indebtedness whether secured or unsecured, absolute or contingent, due or to become due, outstanding on the date of this Indenture or thereafter created, incurred, assumed, guaranteed or in effect guaranteed by the Company, including all deferrals, renewals, extensions or re-fundings of, or amendments, modifications or supplements to, the foregoing [with certain exceptions]. (Emphasis added).1

This case primarily involves the construction of one clause and one term in the Convertible Notes Indenture. One is the italicized clause, “including, with respect to the Credit Facility, all interest accrued subsequent to the commencement of any bankruptcy or similar proceeding, whether or not a claim for post-petition interest is allowable as a claim in any such proceeding. ” The other is the definition of one of the terms used in that clause, “Credit Facility,” which is defined in § 1.01 of the Convertible Notes Indenture as:

that certain Loan Agreement dated as of June 18, 1997, as amended, among the Company, certain subsidiaries of the Company and LaSalle Bank National Association, including all related notes, guarantees, collateral documents, instruments and agreements executed in connection therewith, as each may be amended, modified, restated, renewed, [333]*333replaced, refinanced or restructured (including, without limitation, any amendment increasing the amount of available borrowing) from time to time. (Emphasis added).

KV’s Issuance of Debt

The background to KV’s issuance of the Convertible Notes and its other debt is largely undisputed. In 1997, prior to the issuance of the Convertible Notes, KV had entered into a credit facility with LaSalle Bank that consisted of a $22.6 million revolver and letter of credit facility, as well as a secured term loan of $3.5 million (the “LaSalle Facility”). The LaSalle Facility was amended several times and at the time of the issuance of the Convertible Notes in 2003 consisted of a $40 million revolving line of credit, a $20 million supplemental revolving line of credit and approximately $12.8 million in term debt. The LaSalle Facility provided that KV could not incur certain new debt unless the debt was “subordinated in right of payment to [KV’s] Liabilities on terms satisfactory to [La-Salle] in each particular case.” (LaSalle Facility, §§ 1.01 and 8.3(c).) There is no dispute that LaSalle consented to the issuance of the Convertible Notes on certain terms and conditions, and as further discussed below, its counsel actually negotiated the language that is critical to a resolution of this dispute. After the issuance of the Convertible Notes, the LaSalle Facility was again amended several times and restated on December 31, 2004, when it consisted of $154.6 million of committed financing. Ultimately, on June 9, 2006, KV entered into a new credit facility (the “2006 Citibank Facility”) in which ten institutions led by Citibank provided it with an unsecured $320 million revolving line of credit. The LaSalle facility was paid off and terminated.

In early 2009, KV was prohibited from manufacturing drugs under a consent decree with the United States Food and Drug Authority (the “FDA”) and an agreement with the United States Department of Justice. It entered into nationwide voluntary recalls affecting most of its products and agreed to cease drug manufacture and distribution until it had satisfied certain requirements imposed by the FDA. Revenues declined dramatically, from $207.8 million in 2008 to $9.1 million in 2010. The 2006 Citibank Facility defaulted, and the debt was accelerated. On February 20, 2009, KV repaid all outstanding amounts due under the 2006 Citibank Facility in full from cash on hand, and the 2006 Citibank Facility was terminated. Thereafter, new financing was not obtained for more than 18 months, and KV funded its operations from cash on hand and cash raised through the sale of assets, tax refunds, and the sale of products manufactured by others but distributed by KV.

The parties differ as to KV’s ability during this 18-month period to obtain financing. Plaintiffs assert that KV was in crisis mode and continuously sought alternate senior financing but was unable to obtain it as long as the FDA prevented KV from undertaking most business operations (see, e.g., Ex. X, Bd. of Dir. Teleconf. Presentation (Apr. 8, 2010) (“senior debt is our goal”)). The Defendants assert that KV’s two financial advisors during that period expressed the belief that it had the ability to obtain financing during this period had it chosen to do so. (See, e.g., Szlezinger Dep., 7/29/2013 at 27:25-28:11). In any event, in September 2010, the FDA granted KV approval for a limited return to the market. That same month, KV entered into a financing arrangement with affiliates of Centerbridge Partners L.P. (“Center-bridge”). This $20 million secured bridge loan (the “Healthcare I Facility”) was refinanced about two months later when KV [334]*334entered into a larger senior secured debt financing package with Centerbridge affiliates (the “Healthcare II Facility”), consisting of a $60 million bridge loan and a commitment for a $120 million multi-draw term loan. The latter commitment was divided into three tranches of debt that would be made available upon KV achieving certain milestones. Apparently, KV did not draw on any of this debt and instead obtained a new facility.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
496 B.R. 330, 2013 Bankr. LEXIS 3501, 58 Bankr. Ct. Dec. (CRR) 128, Counsel Stack Legal Research, https://law.counselstack.com/opinion/silver-point-finance-llc-v-deutsche-bank-trust-companyamericas-in-re-k-v-nysb-2013.